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Background: Glyburide has replaced insulin as the first line of therapy in the treatment of gestational diabetes in the
United States. Glyburide and metformin therapies were reported to be comparable to insulin yet also cost-effective,
patient-friendly, and potentially compliance-enhancing. Recently, the efficacy of the use of these oral hypoglycemic
drugs has been questioned. In this review, the questionable concerns will be addressed: Which diabetic drug(s) cross
the placenta? What is the quality of evidence and the data source validity? Which treatment modalities are most
effective in reducing the primary outcome in GDM? Which drug is most effective in improving secondary outcomes?
Findings: This review documents the methodological issues in study design that have impacted the results for the
provision of health care interventions in GDM. The review summarizes the contents of the articles qualitatively and
assesses the theoretical and empirical evidence. Multiple types of studies exist and every study design serves a specific
purpose. Different study designs addressing the same question can yield varying results. The risk of presenting uncertain
results without categorically knowing the direction and magnitude of the effect holds true for both randomized and
nonrandomized controlled trials. The review further emphasizes the importance of achieving the targeted levels of
glycemic control.
Conclusion: The implications of this review are critical to addressing the current gaps in the literature on the
efficacy of the use of oral hypoglycemic agents in GDM. The emphasis needs to be placed on patient treatment
in order to manage hyperglycemia to reduce fetal and maternal morbidity. In this regard, we need to delineate
proper outcome criteria that will reflect disease severity and treat using appropriate pharmacological therapy.
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The time has come to place the emphasis on patient
treatment of gestational diabetes mellitus (GDM) in
order to manage hyperglycemia to reduce fetal and ma-
ternal morbidity rather than debating the diagnostic cri-
teria. We need to clearly define outcome criteria that
reflect the severity of the disease and the appropriate
pharmacological therapy to treat it. Then, randomized
and/or other well-designed studies should be performed
to demonstrate improvement in perinatal outcome with
justified cost of care.
The current American Diabetes Association and
European Association for the Study of Diabetes recom-
mendations state that achieving specific glycemic goals can
substantially reduce morbidity. Thus, effective treatment ofCorrespondence: odlanger@gmail.com
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mately 35-70 % of GDM women will require pharmaco-
logical treatment during pregnancy to achieve glycemic
goals [2].
Historically, insulin has been the recommended treat-
ment for GDM in the U.S. when dietary and lifestyle
measures have failed. Today, randomized controlled tri-
als support the efficacy and short-term safety of glybur-
ide (pregnancy category B) and metformin (pregnancy
category B) in the treatment of GDM [3, 4]. The stress
free use and low cost of these oral hypoglycemic agents
are advantages in comparison to insulin use. These dem-
onstrated advantages have led to a change in clinical
practice. Several guideline bodies, including the Ameri-
can College of Obstetrics and Gynecology [5], the UK
National Institute for Health and Care Excellence, [6]
and the Canadian Diabetes Association [7] endorsed the
use of glyburide. Insulin, metformin, and glyburide todaydistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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mon sense and good clinical judgment should prevail
with adjustments for individual preferences, comorbidi-
ties, and other patient factors.
In the United States, glyburide use increased from
7.4 % of pharmacological treatment to 64.5 %, supersed-
ing insulin as the most common treatment in 2007. Gly-
buride has replaced insulin as the more common
pharmacotherapy for GDM over the past decade [8].
Therefore, it is remarkable that recent studies of glybur-
ide have questioned its use. These studies reported that
fetal plasma glyburide concentrations in humans were
approximately 70 % of maternal plasma levels [9, 10].
Moreover, 2 observational studies [11, 12] posted warn-
ings about safety issues with the use of glyburide. In this
review, several research gaps will be addressed:
1. Which diabetic drug(s) cross the placenta?
2. What is the quality of evidence and data source
validity?
3. Which treatment modalities are most effective in
reducing the primary outcome in GDM?
4. Which drug is most effective in improving
secondary outcomes?
Findings
Which diabetic drug(s) cross the placenta?
It is important to note that when measuring placental
transfer, one needs to understand the limitations of the
measurement system and the unit of measure. 1 mg =
1,000 microgram (μg); 1 μg = 1,000 nanograms (ng);
therefore, 1 mg = 1,000,000 ng. Two systems were used
to measure placental drug concentration. One is high-
performance liquid chromatographic analysis (HPLC-
UV) and the mass spectrometry (LC-MS/MS). Compari-
son of glyburide concentration measured by each system
revealed a strong association (y = 0.9321x + 6.9427, r2 =
0.9597). However, the level of sensitivity for detection is
different in each system.
The majority of drugs used in pregnancy cross the pla-
centa although very few will cause adverse fetal outcome.
Transfer of drugs across the placenta is affected by: mo-
lecular weight, protein kinase A (pKa), lipid solubility,
placental blood flow, blood protein binding, elimination
half-life and the specific placental transport system that
affects the ability of drugs to enter the fetal compartment.
In glyburide, protein binding is greater than 99 %; it
has a short elimination half-life time (6–8 hrs.); the pKa
of 5.3 makes glyburide ionize in plasma making it trans-
portable; transport against the concentration gradient
from fetus to mother provides a concentration ratio
0.92 ± 0.23; and finally, effluxing glyburide by specific pla-
cental transporters. These mechanisms suggest minimal to
no transfer of glyburide to the fetal compartment [2].The recirculating single-cotyledon human placental
model is widely used to characterize the transport and
metabolism of numerous drugs and nutrients. It has
been recognized as an in vitro surrogate for human pla-
cental transfer. It facilitates the study of intact human
placenta independent of fetal metabolism. Finally, each
experiment can be validated with the addition of antipy-
rine as a reference point for the level of transfer.
Our group [3] demonstrated, using HPLC/UV, that in
cord blood samples, minimal glyburide levels (<14 ng/mL)
were detectable despite maternal plasma levels of 50-
150 ng/ml. Even with increased concentration of gly-
buride to 100 times the therapeutic level, transport was
not appreciably altered. The finding of similar cord-
serum insulin concentrations in our two treatment
groups also indicates that little, if any, glyburide reached
the fetuses. This result confirms in vitro studies [13, 14]
in which no maternal-fetal or fetal-maternal transfer of
glyburide was detected in full-term placentas perfused
immediately after delivery. In addition, glyburide has no
effect on the placental transport and uptake of glucose.
Furthermore, maternal hyperglycemia does not alter gly-
buride transfer in vitro. In summary, there was virtually
no significant transport of glyburide in either maternal-
to-fetal or fetal-to-maternal directions with an average
transport of 0.26 % at 2 h. Our findings of negligible gly-
buride transfer across the placenta were reconfirmed by
multiple studies using the single cotyledon model [2].
Two recent studies of glyburide placental transport
in vivo have caused a furor in the literature [9, 10].
Hebert et al. used LC-MS/MS for the determination of
glyburide levels below 10 ng/ml. Maternal blood concen-
trations ranged from non-detectable to 32.7 ng/ml. The
umbilical venous concentrations ranged from non-
detectable to12.5 ng/ml. with a mean of approximately
1 ng/ml. Her findings confirmed our original studies of
negligible glyburide levels in the fetal compartment.
Hebert et al. [9] reported that the mean maternal-fetal
concentration ratio of glyburide was 0.7 ± 0.4. However,
concentration is time dependent. Fetal-maternal ratio is
the result of a given concentration at a single point in
time. Thus, the drug concentration and the ratio are
affected by the time of obtaining the sample and the
sampling technique used. In our study, [3] the time
from administration to obtaining the fetal sample was
8 ± 4 hours with a maternal concentration 50–150 ng.
In Hebert’s study [9], the time was up to 13 hours with
maternal concentration 0.13-32.7 ng. In Schwartz et al.
[10], the time was 13.3 ± 6.5 hours with maternal con-
centration 15.4 ± 20.8 ng with a range of 0.93-70.71.
Schwartz et al., [10] using LC-MS/MS, found in 15 of
the 19 umbilical samples that glyburide concentration
was <10 ng/ml. Seven of the 19 umbilical samples showed
a higher glyburide concentration than the maternal sample,
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10 ng/mL. The overall cord glyburide mean was 7.56 ± 8.2,
with a median of 3.7. In summary, all three studies re-
ported negligible levels of glyburide in the fetal compart-
ment. However, the time of sampling differed in each study
resulting in different maternal concentrations which, in
turn, affects the glyburide concentration ratio between the
mother and fetus.
Does metformin cross the placenta?
Vanky, et al. [15] demonstrated that metformin passes
freely across the placenta and fetal serum levels are com-
parable with maternal values in polycystic ovary (PCO)
patients. Tertti, et al. [16] examined in vivo placental
transfer of metformin in 217 GDM patients randomized
to metformin or insulin. Metformin concentration was
determined in maternal serum at 36 weeks gestational
age and at delivery. Umbilical cord blood was also ob-
tained at birth. The median umbilical cord/maternal
serum metformin concentration ratio was 0.73. Since
metformin is a polar positively charged compound, an
effort was made to characterize its permeability across
the human placenta using the ex vivo placental perfusion
model. It was found that metformin permeability across
the placenta is mediated by a carrier that transports cat-
ionic compounds bi-directionally, with a higher transfer
rate from the fetal to the maternal side [17, 18].
And what about Insulin?
Despite existing dogma that insulin does not cross the
placenta, already in the early 80s, it was demonstrated
that beef-pork-insulin (antibody) crosses the placenta
probably by changing the formation (size) of the anti-
body insulin complex [19]. More than two decades later,
Lindsay et al. [20] reported that insulin antibodies were
detected in the cord blood of 95 % of offspring at birth.
McCance et al. [21] evaluated the presence of insulin
antibodies and their effect on placental transfer with in-
sulin aspart and human insulin. They concluded that in-
sulin antibodies do not develop during pregnancy with
the use of aspart in type 1 diabetes and that 1-5 % of hu-
man insulin concentration was transferred to the fetal
circulation. Boskovic et al. [22] found that no placental
transfer could be detected during the perfusion of insu-
lin lispro with 100 and 200 micro U/ml. In contrast,
concentration-dependent transfer to the fetus was shown
at 580 micro U/ml and higher. Maternal serum level
of ≥ 580 U/ml is equal to approximately 75 units of in-
sulin. The authors concluded that insulin lispro is un-
likely to cross the placenta at a single standard dose
and is also unlikely to reach or harm the unborn baby.
Their conclusion was based on the assumption that type 2
and GDM women will probably not receive this amount
of insulin. However, this is an erroneous conclusion.GDM and type 2 patients are often overweight and obese,
many morbidly obese, characterized by insulin resistance
and, therefore, require much larger insulin doses (1–2
units/kg).
In a study of long-acting insulin analogs, the authors
suggested that glargine probably does not cross the pla-
centa [23]. Pollex et al. [24] added insulin glargine to the
maternal compartment. Experiments were carried out at
therapeutic levels 150, 225, and 300 mmol/l. Concentra-
tions of 150pmol/l showed no detectable insulin levels
in the fetal compartment. However, after perfusion with
concentrations of 150, 225 and 300 nmol/l, the rate of
transfer remained low. Thus, transfer begins when the
glargine dose is >0.3 unit/kg. The authors concluded
that insulin glargine, when used at the therapeutic con-
centrations, is not likely to cross the placenta. Again,
these are flawed conclusions. They are based on the as-
sumption that their designated therapeutic level is univer-
sal; it is not. We must all acknowledge that therapeutic
levels will be different in different centers related to policy,
rate of patients that achieve targeted glycemic goals,
obesity, etc.
The view that the placenta is an absolute barrier to
drugs is completely inaccurate. The fetus is to some ex-
tent exposed to all drugs taken by the mother. There is,
however, sufficient evidence to suggest that the placenta
is capable of limiting fetal exposure to the drug espe-
cially in the case of glyburide. What is important for all
drugs, be it oral to insulin, is not which cross the pla-
centa and to which extent, but rather which ones may
adversely affect the fetus. To date, thousands of patients
have been treated with glyburide, metformin and insulin
during pregnancy with no teratogenic effects on the
fetus. Patients should not be denied the better treatment
option and benefits provided by these drugs; at the same
time, future investigations should continue to determine
their safety just as they would for any other drug in
pregnancy.
What is the quality of the evidence and data
source validity?
Validity is one of the main concerns in research because
it applies to both design and methodology. Most errors
of validity can be traced to problems with data collec-
tion. Therefore, the basic question remains, does the re-
search really measure what it claims to be measuring?
Grimes, et al. addressed this major concern in 2 thought-
provoking articles [25, 26].
Sources of data abstracted from administrative data-
bases or birth certificates have become expedient and
trendy for the potential researcher. However, they are
not epidemiologic research data. They are solely the bur-
eaucratic foundation for claims made for services by
health care providers and institutions. They are, in fact,
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related to the probability of reimbursement. These data-
bases were never intended as sources for epidemiologic
research because they contain only basic demographic
and medical information. They have considerable limita-
tions that must be taken into consideration and should
be used solely to abstract information for which they
were intended, i.e., billing [8].
For example, an administrative database will rarely, if
at all, specify a particular drug (glyburide, metformin,
acarbose, etc.) to which the patient was prescribed or ex-
posed but rather will indicate that the patient was pre-
scribed, “an oral agent.” It has been shown that only
59 % of diagnoses in administrative databases were con-
firmed by actual chart review [27].
Two examples of studies whose data were abstracted
from administrative databases demonstrated some of the
above limitations. In the study by Castillo, et al. [11], the
authors could not ascertain the severity of GDM because
of missing data from glucose tolerance tests. The omis-
sion of race/ethnicity as well as gestational age in the
database precluded the possibility to determine large or
small for gestational age infants as potential con-
founders. They were also limited to the ascertainment of
obesity through the use of the International Classifica-
tion of Diseases (Ninth revision clinical modification)
[ICD-9-CM] diagnosis code and could not, therefore,
rule out the possibility of the effect of obesity on choice
of treatment. In addition, there was failure to provide in-
formation on drug dosage. It has become the standard
of care that achieving targeted levels of glycemic control
is paramount for treatment of GDM women. But, no
glucose data during pregnancy was available. A priori, an
inability to evaluate the impact of the level of glycemic
control during pregnancy should disqualify any study ad-
dressing outcome of diabetes in pregnancy Table 1.Table 1 Comparison of Administrative Database Studies
Castillo et al. [11]
Glyburide Insulin R.R 95 %
N = 4982 N = 4191
LGA 4.7 % 3.2 % 1.43 (1.1
Macrosomia n.a. n.a. —
Hypoglycemia 1.9 % 1.3 % 1.40 (1.0
Jaundice 0.3 % 0.4 % 0.96 (0.4
Neonatal RDS 2.9 % 1.7 % 1.63 (1.2
Preterm 9.5 % 8.9 % 1.06 (0.9
NICU admission 10.2 % 7.2 % 1.41 (1.2
Birth injury 2.2 % 1.6 % 1.35 (1.0
Cesarean delivery 50.6 % 52.5 % 0.97 (0.9
n.a. = not available, LGA = large for gestational age, NICU = neonatal intensive careCheng’s, et al. study [12] further exposed the limita-
tions of the administrative database. The authors con-
ducted a retrospective cohort study of women diagnosed
with GDM who required pharmaceutical therapy. They
were enrolled in the Sweet Success California Diabetes
and Pregnancy Program between 2001 and 2004, a
California state-wide program. Although they sought to
compare insulin and glyburide treated women, the data-
base did not include a variable for a glyburide recipient.
Rather, the variable was indicated as “oral agent.” Thus,
the authors speculated that all oral agents prescribed
were glyburide. The second major limitation of the study
was the lack of glucose data throughout pregnancy. In-
formation on neonatal metabolic, respiratory, previous
macrosomia or birth trauma data was also not reported
Table 1.
The use of administrative databases results in very
large sample sizes which, in turn, can lead to spurious
statistical associations (“mass significance”). Although
the sample size can demonstrate statistical significance,
the results may not always be clinically significant. A
large sample size, containing confounders, can be chal-
lenging when there are weak associations. Risk levels of
1 and 2 should be considered questionable because they
may represent potential bias. They are more of a com-
motion than a signal to consider clinical changes. In
general, unless relative risk (RR) in cohort studies exceed
2 to 3 or odds ratios (OR) in case–control studies exceed
3 or 4, associations in observational research findings
should not be considered credible. [25, 26, 28] Table 1.
Which treatment modalities are most effective in
reducing primary outcome in GDM?
It has been generally acknowledged that abnormal levels
of glycemia result in adverse pregnancy outcome in
GDM. Therefore, the achievement of targeted levels ofCheng et al. [12]
C.I. Glyburide Insulin O.R. 95 % C.I.
N = 2073 N = 8604
6-1.76) 17.6 % 19.0 % 1.03 (0.83-1.20)
13.4 % 13.1 % 1.29 (1.03-1.64)
0-1.95) n.a. n.a. —
8-1.91) n.a. n.a. —
3-2.15) n.a. n.a. —
3-1.00) n.a. n.a. —
3-1.62) 8.1 % 6.5 % 1.32 (1.07-2.00)
0-1.82 n.a. n.a —
3-1.00) 38.8 % 44.9 % 0.77 (0.65-0.91)
unit
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Moreover, the majority of studies evaluating the efficacy
of glyburide in comparison to insulin used success of
achieving glycemic control as the primary outcome vari-
able. Table 2 Appropriately designed randomized con-
trolled trials, or prospective and retrospective studies,
with the correct sample size and clear definitions of well
and poor glycemic control will maximize production of
accurate data [28].
As a rule of thumb, the ability of studies to duplicate a
finding is the gold standard of science. Reproducibility
of a study is often a rare occurrence. However, regardless
of the research design, the majority of studies have con-
sistently demonstrated that insulin and oral agent
treated patients (glyburide and/or metformin) achieved
the desired level of glycemic control Table 2.
What we don’t yet definitely know is whether metfor-
min or glyburide is the more effective oral hypoglycemic
agent. Silva et al., [30, 31] in 2 randomized clinical trials
(RCTs) comparing metformin to glyburide, concluded
that the achieved levels of glycemia were comparable for
both drugs. In addition, there was no difference in peri-
natal results: cesarean section (C/S), large for gestational
age (LGA), neonatal hypoglycemia, or rate of neonatal
intensive care unit (NICU) admission [31].
In contrast, Moore et al. [32] in a randomized study
showed that the failure rate to achieve the glycemic tar-
get was 34.7 % for metformin and 16.2 % for glyburide.
In a recent randomized clinical trial (RCT) study, ZoharTable 2 Achievement of Glycemic Control by Study Design and Tre
Design Patient No. Oral/Insulin
Langer’00 [3] RCT 201 / 203
Lain’09 [50] RCT 41 / 41
Bertini’05 [51] RCT 24 / 27
Ogunyemi’07 [52] RCT 48 / 49
Tempe’13 [53] RCT 32 / 32
Silva’07 [54] RCT 36 / 36
Rowen’09 [4] RCT 363 / 370
Moore’07 [32] RCT 31 / 32
Spaulonci,’13 [55] RCT 47 / 47
Tertti’13 [16] RCT 110 / 107
Niromanesh’12 [56] RCT 80 / 80
Ijas’11 [57] RCT 50 / 50
Ramos’07 [43] Retrospective 122
Jacobson’05 [58] Retrospective 236 /268
Conway’04 [37] Retrospective 75
Yogev’10 [38] Retrospective 124
Rochon’06 [39] Retrospective 101
Kahn’06 [40] Retrospective 95et al., [33] found that metformin vs. glyburide failed to
achieve targeted glycemic levels 29 % vs. 22 %, p = 0.41,
respectively. The obstetrical and neonatal outcomes
were comparable including anthropometric measures,
cord blood insulin and C-peptide. In addition a meta-
analysis demonstrated that both metformin and glybur-
ide are as effective as insulin in the management of
GDM [34]. The above studies demonstrated comparable
success rates and in one a higher failure rate with met-
formin. However, it is remarkable to note that a meta-
analysis [35] reported in favor of metformin for maternal
weight gain (mean difference −2.06 kg (−3.98 to −0.14),
birth weight (mean difference −209 g (−314 to −104),
macrosomia (risk ratio 0.33 (0.13 to 0.81), and large for
gestational age newborns (risk ratio 0.44 (0.21 to 0.92),
even when treatment failure was higher with metformin.
If studies cited are at best inconclusive, meta-analysis
simply magnifies the impact of poor quality data.
Disease severity is another factor that influences the
success rate in the achievement of targeted glucose levels.
The greater the disease severity as reflected by the fasting
plasma glucose, success rates to achieve adequate levels of
glucose decrease. However, the rates of success remain
comparable for glyburide and insulin treated patients at
all severity levels [36]. The question remains, how success-
ful are those who failed to achieve glycemic control with
either glyburide or metformin after transfer to insulin.
The rate of success for achieving glycemic control in met-
formin treated patients ranged from 54-79 %. The successatment Modality
Oral type Well control Oral / Insulin Comparison of control
glyburide 82 % vs. 88 % similar
glyburide 91 % vs. 97 % similar
glyburide 79 % similar
glyburide 93 % similar
glyburide 91 % vs. 94 % similar
glyburide — similar
metformin 54 % for Metformin
metformin MBG similar
metformin 74 % similar
metformin 79 % similar
metformin 86 % similar
metformin 68 % similar
glyburide 84 % for glyburide
glyburide 86 % vs. 63 % dissimilar
glyburide 84 % similar
glyburide 75 % similar
glyburide 81 % similar
glyburide 81 % similar
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date, there is no reported data for success of metformin
patients transferred to insulin.
The success rate for achieving glycemic control with
glyburide ranged from 75-84 %. Transfer failure from
glyburide to insulin ranged from 54-67 %. In a logistic
regression evaluating predictors of glyburide failure, the
main predictor was glyburide dose (O.R. 3.73 95 %, C.I.
2.15-6.48). In addition, there was a weak association
(potential bias) for disease severity (O.R. 1.58) and no
association to body mass index (BMI), previous GDM,
and ethnicity.
Given the approximate doubling in glyburide clearance
during pregnancy, should we increase the starting and
maximal dose during pregnancy? [9] From the scientific
perspective, it is important to understand the pharmaco-
kinetic and pharmacodynamic considerations. However,
in the clinical, real world environment, drug manage-
ment decisions need to be determined based on patient’s
diet, weight and ethnicity. In our study, 31 % of GDM
subjects achieved targeted levels of glycemic control
with a 2.5 mg dose. Twenty-seven percent required
5 mg; 21 % - 10 mg; 9 % - 15 mg; and, only 12 % re-
quired the maximal dose of 20 mg [36]. Thus, approxi-
mately 2/3 s of the patients achieved targeted levels of
glycemic control with less than 50 % of the maximal
dose. The amount and frequency of drug administration
will both determine the optimal therapeutic effect. The
lower limit for glycemic benefits of glyburide are nearly
fully realized at half-maximal dose and higher doses
should generally be avoided. The upper limit of the
range is such that no more than 5-10 % of subjects will
experience a toxic effect is a major consideration [41]. In
light of this clinical data, it is possible that combination
therapy with a lower dose of each medication should be
considered in order to successfully maximize glucose
control. The goal is to provide drug efficacy without un-
acceptable toxicity.
Which drug is most effective in improving secondary
outcomes?
A well planned and executed RCT is the gold standard
in study design. However, the outcome results that are
measured in a single specific trial cannot be regarded
as absolute proof. Ioannidis concluded, “Controversies
are most common with highly cited nonrandomized
studies, but even the most highly cited randomized tri-
als may be challenged and refuted over time, especially
small ones” [28].
Different study designs that address the same research
question will yield varying results. There is risk of pre-
senting uncertain results for both nonrandomized and
randomized controlled trials when there is questionable
knowledge if the direction and magnitude of the effectholds true [42]. The majority of maternal and neonatal
complications are the result of maternal hyperglycemia
that in turn causes fetal hyperinsulinemia. In our RCT
we showed that neonatal cord insulin (μU) was similar
in glyburide and insulin treated patients (14 ± 4 vs. 15 ±
2.3 respectively) [3]. Ramos et al., in a retrospective
study compared glyburide vs. insulin treated GDMs.
Neonatal hypoglycemia was defined as <45 mg/dl within
1 h of birth. There was no difference between glyburide
and insulin, 23 % vs. 27 %, p = 0.58 [43]. Finally, 2 meta-
analyses concluded that neonatal hypoglycemia is not as-
sociated with glyburide therapy [44, 45].
How does glyburide affect the mother?
Yogev et al., [46] using continuous glucose monitoring
(CGM) found asymptomatic hypoglycemic episodes in
63 % of insulin and 28 % of glyburide treated subjects.
Brustman et al. [47] with a large sample size studied the
effect of glyburide therapy on the number of episodes of
maternal hypoglycemia in patients using self monitoring
blood glucose (mean of 310 ± 190 samples/patient).
When hypoglycemia was defined between 40–50 mg/dL,
65 % of subjects had no episodes. When the maternal
hypoglycemia definition was <40, over 90 % had no epi-
sodes of hypoglycemia. Overall, only 2–3 episodes were
found in a minority of patients (~2-4 %).
Several outcome variables are used as secondary out-
come measures in the majority, if not all studies, address-
ing diabetes in pregnancy. These variables are associated
with maternal hyperglycemia which in turn causes fetal
hyperinsulinemia. Fetal hyperinsulinemia has been shown
to be associated with metabolic complications (hyperbilir-
ubinemia, hypoglycemia, respiratory complications, and
polycythemia) and the resultant macrosomia/LGA and
shoulder dystocia. However, it should be noted that these
complications are mainly the result of abnormal glucose
levels. In addition, different secondary outcome variables
have different weighted importance since some are transi-
tory while others have long term impact on the neonate.
The secondary outcomes in the largest randomized
and retrospective studies are compared in Table 3.
Within each of the three studies, no significant differ-
ence was found in any of the secondary outcome vari-
ables. In contrast, the rate of several outcome variables
among the three studies was significantly different, (e.g.
LGA, macrosomia) probably due to failure to achieve
targeted levels of glycemic control. Again, this compari-
son reemphasizes that the cornerstone for the successful
treatment of GDM is the control of the level of glycemia
and not the pharmacological treatment modality.
Systematic reviews and meta-analyses have become in-
creasingly important in health care. Clinicians read them
to keep up to date in their field and they are often used as
a starting point for developing clinical practice guidelines.
Table 3 Summary of Secondary Outcome Results
Rowen et al. [4] Langer et al. [3] Jacobson et al. [58]
Randomized Randomized Retrospective
Metformin Insulin Glyburide Insulin Glyburide Insulin
n = 363 n = 370 n = 201 n = 203 n = 236 n = 268
LGA 19.3 % 18.6 % 12.0 % 13.0 % 25.0 % 24.0 %
Ponderal Index >2.85 — — 9.0 % 12.0 % — —
Macrosomia 22.9 % 21.4 % 7.2 % 4.7 % 25.0 % 24.0 %
Hypoglycemia 15.2 % 18.6 % 9.0 % 6.0 % 31.0 % 27.0 %
Hyperbilirubinemia 8.0 % 8.4 % 6.0 % 4.0 % 25.0 % 22.0 %
Phototherapy — — — — 9.0 % 5.0 %
Polycythemia — — 2.0 % 3.0 % — —
RDS 3.3 % 4.3 % 2.0 % 3.0 % — —
5 min Apgar 0.8 % 0.3 % 3.1 % 4.2 % — —
NICU admission 12.7 % 12.2 % 6.0 % 7.0 % 15.0 % 24.0 %
Shoulder dystocia — — 1.5 % 1.6 % — —
Preeclampsia 8.3 % 6.8 % 6.0 % 6.0 % 12.0 % 6.0 %
Chronic hypertension 8.5 % 7.3 % 6.0 % 9.1 % — —
Cesarean delivery 22.9 % 21.4 % 23.0 % 24.0 % 39.0 % 35.0 %
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sure there is justification for further research. As with all
research, the value of a systematic review depends on
what was done, what was found, and the clarity of the re-
ported results [48].
Meta-analysis [25, 26, 42] was originally designed for
low prevalence conditions to produce hypotheses for fu-
ture studies. Moreover, including observational studies,
in addition to randomized trials, is at best controversial
[44, 45]. Several meta-analyses of randomized controlled
trials addressing oral agents have been published.
However, verification of the methodology and the stat-
istical analysis used in each study are not feasible be-
cause the raw data are not available. However, the
chance for error(s) is much less in a single study than
in a systematic review or meta-analysis. Different de-
signs addressing the same question often yield differ-
ences in the results.
For example, in the meta-analysis comparing glyburide
to insulin, the largest study contained 404 subjects [3]
while each of the other seven studies had fewer than 100
participants for a total of 384 patients Tables 2 and 4.
Most of the individual studies were not statistically pow-
ered to examine the less common neonatal complica-
tions that can be associated with hyperglycemia, such as
macrosomia or hypoglycemia. This is of even greater sig-
nificance when not all seven studies were included in the
analysis for each complication. Jiang et al. [34] used 2
studies for the evaluation of cesarean section, and 5 for
macrosomia. Zeng et al. [49] reevaluated the rate ofneonatal hypoglycemia when only 3 RCTs were included.
Euclid, the father of geometry, taught us that the whole is
equal to the sum of its parts. However, in meta-analysis,
not all parts are equal and very often they are not neces-
sarily included in the whole. A meta-analysis can be no
better than its component parts.
Table 4 compares 6 meta-analyses with their com-
ponent studies. The similarities between the studies
suggest that there will be comparable results from
each meta-analysis. Table 5 compares the outcome in
each meta-analysis demonstrating similarity on the
one hand and differences on the other. The combin-
ation of dissimilar studies can devalue the relevance
of any meta-analysis.
Outcome definitions and vigorous ascertainment of re-
sults were not always provided in the studies. In some
outcomes such as preterm birth, caesarean section, birth
weight, and Apgar score, there is agreed consensus on
definitions. In contrast, in those variables where defini-
tions and detection protocols are less universal, greater
differences, i.e., neonatal hypoglycemia, respiratory dis-
tress, jaundice, and admission to the neonatal intensive
care unit, will result in varying rates in each individual
study. For neonatal hypoglycemia, different definitions
have been used in the studies with criteria ranging from
45 to less than 25 mg/dl and using from 1–9 blood de-
terminations. In addition, in some studies, administra-
tion of I.V. glucose to neonates will classify them as
hypoglycemic regardless of the actual blood glucose
reading [Tables 4 and 5].
Table 4 Individual Studies Included in the Various Meta-Analyses
Dhulkotia [45] Poolsup [59] Balsells [35] Zeng [49] Jiang [34] Gui [60]
Metformin studies
Moore [32] + + + — + +
Rowan [4] + + + — + +
Niromanesh [56] — + + — + +
Ijas [57] — + + — + +
Spaulonci [55] — + + — + —
Tertti [16] — + + — + +
Silva [31] — — — — — —
Hassan [61] — — — — + —
Hague [62] — — — — + —
Therapy efficacy n.a. similar similar n.a. similar similar
Glyburide studies
Silva [54] + + + + + —
Tempe [53] — + + + + —
Bertini [51] — — — + + —
Ogunyemi [52] + + — + + —
Langer [3] + + + + + —
Lain [50] — — + + + —
Mukhopad-hyay [63] — + + + — —
Therapy efficacy similar dissimilar dissimilar similar suitable n.a.
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The introduction of glyburide and metformin in the
treatment of gestational diabetes has profoundly altered
the management approach with comparable outcomes
to insulin therapy. These therapies are cost-effective,
patient-friendly, and potentially compliance-enhancing.
Therefore, there may be greater risk to the fetus in
withholding these medications than in prescribing
them.Table 5 Results of 6 Meta-Analyses Comparing Glyburide to Insulin




Macrosomia similar Increase O.R. 2.34 Inc
LGA similar similar sim
Neonatal hypoglycemia similar Increase O.R. 2.06 Inc
Neonatal hyperbilirubinemia. n.a. similar sim
Preterm n.a. similar sim
NICU admission n.a. similar sim
Preeclampsia n.a. similar sim
Cesarean delivery similar similar sim
n.a. = not available
In Moretti and Dhulkotia, the meta-analyses included observational and RCT studiesThe outcome of a clinical debate depends on the
adequacy of the respective accounts of existing data.
Some types of counter explanations to a concept lack
consistency and predictability very often because of
faults in validity, i.e. the methodology did not measure
what should have been measured. Nevertheless, despite
occasional vague explanations, science is better off being
tolerant of second-guessers. Science should have both a
conservative bias – which prevents rapid and bewilderingTherapy
sells 2015 [35] Zeng 2014 [49] Jiang 2015 [34] Moretti 2008 [44]
similar similar suitable similar
rease R.R. 2.62 Increase R.R. 2.22 Increase O.R 3,09 similar
ilar similar n.a. similar
rease R.R.2.04 Increase O.R. 1.98 Increase R.R. 2.64 similar
ilar n.a. n.a. n.a
ilar similar similar n.a.
ilar similar similar similar
ilar — similar n.a.
ilar similar similar n.a.
in addition to insulin and metformin studies
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sistent innovators can ultimately triumph if their claims
actually merit consideration. In the words of T.S. Elliot,
“Where is the wisdom we have lost in knowledge? Where
is the knowledge we have lost in information?”
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